|Direct Targets Identification of a Bioactive Compound|
Sylvain Blanc, Paul Bradley, Marie-Edith Gourdel, Michael Cholay, Gisèle Guimèse, Mike Mckenzie, George Nasi, Jean-Christophe and Barbara Ruggiero
Identifying protein partners of a small bioactive molecule is of great
interest in many aspects of life sciences and specifically in the drug
discovery and development process cycle. It is a support to (i) decipher
the mechanism of action after for example a “High Content” screening,
(ii) study “off-target” effects, (iii) adjust therapeutic indications and
clinical regimens of a drug and (iv) consider drug repositioning.
|3D-Tissue/ Whole-blood Co-culture Models Combined with Multi-Analyte Profile (MAP) Analyses for In-vivo-like Immunopharmacology|
Stein GM, Joos T, Schmolz M
Human Organotypic Test (HOT) Systems aim at in-vivo like substance characterisation of all preparations meant to act on the human immune system.
|Phenotypic Screening Applied to the Anti-biofilm Drug Discovery: Identification of Anti-biofilm Flavonoids from a Chemical Library|
Suvi Manner1*, Malena Skogman2, Pia Vuorela2, Adyary Fallarero2
This work represents a systematic exploration of a flavonoids collection for the inhibitory activity against Staphylococcus aureus biofilms and offers an improved methodological workflow for anti-biofilm screens of chemical libraries taking into account the connections between anti-biofilm and antibacterial properties.
|EU-OPENSCREEN - The European Research Infrastructure of Open Screening Platforms for Chemical Biology|
EU-OPENSCREEN (www.eu-openscreen.eu) is the largest emerging academic chemical biology research infrastructure initiative in Europe with the aim to collaboratively develop novel research tool compounds with external scientists. As a joint effort of national networks in 16 European countries, EU-OPENSCREEN offers access to high-throughput screening platforms, chemistry services, an open-access database, a large compound collection and an open-access database.
|Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"|
Pilar Ventosa-Andrés, Nils Ohnesorge, Yolanda Fernández, Yolanda Alvarez and Breandán Kennedy
3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.
|Direct flow synthesis of H2O2 catalysed by palladium supported on sulfonated polystyrene resins|
Aurélie Plas, Eduard Dolušic and Steve Lanners
Development of a continuous microfluidic process for the production of hydrogen peroxide by direct synthesis with a minimalised ecological footprint.
|Idebenone Inhibits Cell Proliferation by Blocking of ANO1/ TMEM16A Chloride Channel in Adenocarcinoma Cells|
Idebenone significantly reduced cell proliferation and induced apoptosis in PC-3, CFPAC-1, HT-29, T-84 and Calu-3 cells having CaCCs activities. These data suggest that idebenone, an ANO1/CaCC inhibitor, has potential for use in cancer therapy.
|Pressure-Based Volume Measurement Technology for In-process Measurement of Microplate Contents|
John Thomas Bradshaw, Bill Gigante, Christoph Schwedes
Modern drug discovery and research labs are utilizing complex automation systems to assist in
high throughput screening of novel drug candidates. A large portion of these laboratories are
using ANSI-SBS-standard 96- and 384-well plates to achieve the necessary throughput. The volume
of sample transferred into and out of these plates can be critical to the success of assays or
validation of procedures.
|Accurate Normalization of Grain Samples Using Pressure-Based Volume Measurement Technology|
Bill Gigante, John Thomas Bradshaw, Tanya Knaide
A common challenge experienced by sample screening facilities is identifying individual sample quantity prior to DNA extraction. Accurately identifying sample quantity allows the user to pipette exact amounts of extraction buffer into each well.